ArticlePediatric transplantation2026
The Association of DQ Donor-Recipient Mismatching on Development of Antibody-Mediated Rejection and Donor-Specific Antibody-Positive Rejection After Pediatric Heart Transplantation.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral studies have shown lower risk of de novo donor specific antibodies (dnDSA) and antibody-mediated rejection (AMR) in adult transplant recipients with less HLA donor-recipient mismatching, particularly at the Class II DQ locus. We aimed to evaluate the association between degree of DQ antigen mismatch and risk for AMR and DSA-positive rejection development in pediatric heart transplant (HT) recipients.
methodsChildren who underwent HT from 2012 to 2023 were identified from the Pediatric Heart Transplant Society registry. Those with available DQB1 donor and recipient data obtained from merge with OPTN were included. Number of DQB1 donor-recipient mismatches (DQB1-MM) (and DQA1 for the limited subset) were determined by comparing donor and recipient HLA data. Primary outcomes evaluated were freedom from biopsy-proven AMR and freedom from DSA-positive rejection. Subset analyses were performed for those with available DQA1 data.
resultsA total of 3672 HT recipients were included; 1302 (35%) had 2 DQB1-MM, 1945 (53%) had 1 DQB1-MM, and 425 (12%) had 0 DQB1-MM. Those with 0 DQB1-MM were more likely to be White than those with 1 or 2 DQB1-MM (67% vs. 63% and 61%, respectively, p = 0.0268). There were no other significant differences in clinical, demographic, or transplant characteristics between the groups. There was no difference in freedom from biopsy-proven AMR based on number of DQB1-MM in either univariable or multivariable analysis. Freedom from DSA-positive rejection was significantly higher in those with 0 DQB1-MM compared to those with 1 or 2 MM (estimated 92% at 5 years posttransplant compared to 81%, p < 0.001). This association remained significant when controlling for other known rejection risk factors in multivariable analysis.
conclusionsFewer DQ antigen mismatches are associated with improved freedom from DSA-positive rejection, but not biopsy-proven AMR in children undergoing first HT. Further study is needed to understand long-term implications of this finding and its potential use in improving posttransplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.